Please login to read the full article.
Scrip Regulatory Affairs
Sins of omission: how the US FDA's social media inaction puts patients and industry at risk
20 April 2011
Bill Drummy
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Higher US generic drugs user fee for foreign units 'discriminatory, anti-competitive', say Indian firms
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
- EU pharmacovigilance legislation implementation likely to be staggered
- US patent reform bill clears Senate, but will it create jobs?
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
